You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Investigators identified five expression subtypes spanning three broader clusters in postmortem parahippocampal gyrus samples from Alzheimer's patients.
The researchers also examined the contribution of rare variants to inflammatory bowel disease to find a potential targetable pathway.
An integrated proteogenomic analysis led to previously unappreciated treatment targets or prognostic markers in craniopharyngioma, high-grade glioma, and other tumor types.
Researchers tested blood samples from urgent and routine care patients seen between early February and early July 2020 for SARS-CoV-2 antibodies.
The screen homed in on a number of genes involved in cholesterol biosynthesis that, when lost, make cells more resistant to infection.
In PLOS this week: immune-related gene pairs linked to malignant melanoma outcomes, plasticity among paramyxoviruses, and more.
In Cell this week: analysis of multisystem inflammatory syndrome in children with SARS-CoV-2, fecal transplants boost gut microbiome development in infants born by C-section, and more.
Methylation profiles of more than 23,000 individuals uncovered thousands of epivariations, including some affecting Mendelian disease genes.
The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.
A computational method, coupled with PCR analysis and RNA-seq, helped researchers pinpoint several drugs that could be repurposed to fight COVID-19.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.